-
Recognizing that patients and consumers are the key players in healthcare, all employees are recommended to spend 1% of their working hours with patients
-
We strive to improve access to medicines through the development and provision of innovative medicines.
-
July 1, 2020
-
June 29, 2020
Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares
-
June 25, 2020
EISAI RECEIVES APPROVAL FOR PARKINSON’S DISEASE TREATMENT EQUFINA® IN SOUTH KOREA
-
June 23, 2020
-
June 19, 2020
-
July 3, 2020
Video about Improving Access to Medicines "Leave No One Behind -Disease of Neglected People-"
-
June 22, 2020
IR "Notice of Shareholder Voting Results for the 108th Ordinary General Meeting of Shareholders"
-
June 22, 2020
-
June 19, 2020
IR "Notice of Resolution of the 108th Ordinary General Meeting of Shareholders"
-
June 12, 2020
-
February 14, 2020
EISAI TO VOLUNTARILY WITHDRAW ANTIOBESITY AGENT BELVIQ® / BELVIQ XR® IN THE U.S.
-
October 18, 2019
EISAI JOINS WORLD ECONOMIC FORUM AS STRATEGIC PARTNER ASSOCIATE
-
July 8, 2019
-
July 4, 2019
-
December 6, 2018
EISAI JOINS WORLD ECONOMIC FORUM CENTRE FOR THE FOURTH INDUSTRIAL REVOLUTION JAPAN
Eisai's hhc Philosophy
Sustainability
28 countries 2.0 billion tablets
Number of countries supplied with lymphatic filariasis treatment
and volume supplied (as of June 2020)
Eisai is promoting initiatives for improving access to medicines to contribute to people in developing and emerging countries
